NovoCure Q4 2025 non-GAAP EPS $-0.22 (+64% YoY) beats estimates while revenue $174.3M (+8% YoY) misses forecasts
Chief Medical Officer Dr. Nicolas Leupin resigns effective Feb. 25, marking a key leadership change.
Chief Innovation Officer Dr. Uri Weinberg will assume Chief Medical Officer responsibilities after Leupin's departure.
Leadership transition is part of a reorganization previously disclosed on Novocure's Q4 2025 earnings call.
For 2026, Novocure guides net revenue to a $675–$705 million range.
2026 adjusted EBITDA guidance is forecast between $(20) million and $0 million.
https://finviz.com/quote.ashx?t=NVCR&p=d
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.